Industry Overview - The cannabis industry is experiencing a positive shift following President Trump's endorsement of cannabidiol (CBD) for senior healthcare, leading to a rally in cannabis shares [1][2] - The U.S.-listed shares of Canadian cannabis companies are seeing significant gains, indicating a strong market reaction [1] Political Influence - Trump's statement on CBD as a potential alternative to traditional prescription drugs may provide momentum for the cannabis industry, which has faced strict regulations [2][3] - The possibility of reclassifying marijuana under federal law could alleviate operational and tax challenges for cannabis businesses, although it would not equate to full legalization [2][3] Market Performance - Analysts highlight that political backing, even if symbolic, is crucial for an industry struggling with regulatory hurdles [3] - The global cannabis market is projected to reach a value of $444.34 billion by 2030, showcasing its high growth potential despite volatility [4] Stock Performance - Notable stock performance includes: - Tilray Brands (TLRY) up 41.3% - Aurora Cannabis (ACB) up 23.6% - Canopy Growth (CGC) up 15.7% - Green Thumb Industries (GTBIF) up 15.7% - Curaleaf Holdings (CURLF) up 20% - Trulieve Cannabis (TCNNF) up 12.7% [5]

Company Earnings - Carnival (NYSE: CCL) reported third-quarter earnings of $1.43 per share, exceeding the analyst consensus estimate of $1.32 per share [2] - The company also reported quarterly sales of $8.153 billion, surpassing the analyst consensus estimate of $8.101 billion [2] Stock Movements - Tilray Brands, Inc. (NASDAQ: TLRY) shares increased by 40% to $1.6050 following a video from President Donald Trump promoting cannabis health benefits [8] - Merus N.V. (NASDAQ: MRUS) shares surged 36% to $93.93 after Genmab agreed to acquire the company for $97 per share [8] - Better Home & Finance Holding Company (NASDAQ: BETR) shares rose 17% to $62.23 after announcing a $75 million at-the-market offering for Class A shares [8] - KALA BIO, Inc. (NASDAQ: KALA) shares plummeted 89% to $2.15 after failing to meet primary endpoints in a clinical trial [8] - MoonLake Immunotherapeutics (NASDAQ: MLTX) shares fell 89% to $6.69 due to a failed trial [8] - IO Biotech, Inc. (NASDAQ: IOBT) shares dropped 78% to $0.3501 following an update after a pre-BLA meeting with the FDA [8] Economic Indicators - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [10] - The Dallas Fed's general business activity index for Texas manufacturing declined to -8.7 in September from -1.7 in the previous month [10]

Core Viewpoint - Cannabis stocks experienced significant gains following President Donald Trump's promotion of a video advocating for the inclusion of cannabidiol (CBD) under Medicare coverage [1][6]. Group 1: Stock Performance - Tilray Brands surged nearly 20% and was up 36% after market open [1]. - Canopy Growth jumped about 20%, while Cronos Group rose 13% [1]. - Aurora Cannabis climbed 13.3%, and Trulieve Cannabis spiked almost 20% [1]. - Green Thumb Industries, Curaleaf Holdings, and Innovative Industrial Properties also saw considerable share price increases [3]. Group 2: Video Promotion and Content - The video produced by The Commonwealth Project features Trump and a narrator advocating for wider access to CBD for seniors [6][9]. - The narrator claims that hemp-derived CBD can significantly improve the quality of life for older adults [7][10]. - The video suggests that CBD can help restore the endocannabinoid system and assist with pain, sleep, and stress [10]. Group 3: Regulatory Context - Trump previously indicated he was considering reclassifying marijuana as a less dangerous substance, although no action has been taken yet [8]. - The timing of the video promotion coincides with Congress deliberating on tightening hemp regulations, with some Republicans advocating for stricter limits on CBD products containing trace amounts of THC [8].

Cannabis Industry & Policy - President Trump shared a video highlighting the health benefits of hemp-derived CBD, potentially revolutionizing senior healthcare as an alternative to costly prescription drugs [1][2] - The 2018 Farm Bill legalized hemp-derived products like CBD [3] - Trump hinted at reclassifying cannabis from a Schedule 1 drug to a less dangerous Schedule 3, alongside steroids and Tylenol with codeine [3] - Reclassification would ease criminal penalties, lift tax burdens on companies, and open the pathway to more medical research [4] - New HHS standards for "accepted medical use" acknowledge widespread physician use and some credible scientific support, rather than demanding full FDA level clinical trial evidence [4] Market Reaction & Stock Performance - Tilray, Canopy Growth, and Aurora are all jumping double digits [2] - The cannabis sector has been volatile, with some stocks halving in value this year and others gaining over 30% [5] - Investors are reacting positively to the news regarding potential reclassification [5] Regulatory Process & Future Outlook - The decision to reclassify cannabis needs to come from the administration [6] - The previous administration did a lot of the work in terms of reclassification, putting forward the DEA's recommendation and opening it for public comment [6] - The current administration has the power to expedite the reclassification process [6] - Rescheduling could move cannabis stocks forward [7]

Core Viewpoint - The cannabis sector is experiencing a surge in stock prices following President Trump's endorsement of hemp-derived CBD, which he claims could revolutionize senior healthcare and serve as an alternative to expensive prescription drugs [1][2]. Industry Developments - Major cannabis companies such as Tilray, Canopy Growth, and Aurora have seen their stock prices jump by double digits in response to the president's comments [2]. - The cannabis sector has been volatile, with some stocks losing value this year while others have gained over 30% [5]. Regulatory Changes - President Trump previously legalized hemp-derived products like CBD through the 2018 Farm Bill and hinted at reclassifying cannabis from a Schedule I drug to a Schedule III drug, which would ease criminal penalties and tax burdens on companies [3][4]. - The reclassification would also facilitate more medical research into cannabis, as new HHS standards acknowledge its accepted medical use and some credible scientific support [4]. Market Implications - The potential reclassification of cannabis could welcome big pharmaceutical companies into the market, although the process remains lengthy [5]. - The current administration has the authority to expedite the reclassification process, which could further impact the cannabis market positively [6].

Market Overview - U.S. stocks exhibited mixed performance, with the Nasdaq Composite increasing by over 100 points on Monday [1] - Cannabis-linked stocks experienced significant gains following President Trump's video promoting the health benefits of cannabis [1] Company Highlights - Tilray Brands, Inc. (NASDAQ: TLRY) saw a sharp increase in shares, rising 39.2% to $1.5983 [1] - Merus N.V. (NASDAQ: MRUS) gained 36.6% to $94.14 after Genmab agreed to acquire the company for $97 per share [4] - Better Home & Finance Holding Company (NASDAQ: BETR) increased by 20.1% to $63.60, supported by a $75 million at-the-market offering for Class A shares [4] - BTQ Technologies Corp. (NASDAQ: BTQ) jumped 20% to $6.36, as Danal began proof-of-concept for BTQ's quantum-secure Stablecoin settlement network [4] - SNDL Inc. (NASDAQ: SNDL) rose 18.8% to $2.77, benefiting from the positive sentiment around cannabis stocks [4] - Innoviz Technologies Ltd. (NASDAQ: INVZ) increased by 15.6% to $1.9701 after Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $1.50 to $2.50 [4] - Sandisk Corporation (NASDAQ: SNDK) shares jumped 14.3% to $111.06 [4] - GDEV Inc. (NASDAQ: GDEV) rose 12.7% to $29.24 [4] - Ondas Holdings Inc. (NASDAQ: ONDS) gained 12.2% to $8.59 [4] - Pony AI Inc. (NASDAQ: PONY) increased by 10.3% to $23.36, with Citigroup initiating coverage with a Buy rating and a price target of $29 [4] - Galaxy Digital (NASDAQ: GLXY) gained 9.5% to $33.85 [4] - Western Digital Corporation (NASDAQ: WDC) rose 9% to $116.48 after Rosenblatt raised its price target from $90 to $125 while maintaining a Buy rating [4] - New Oriental Education & Technology Group Inc. (NYSE: EDU) increased by 5% to $53.85, with B of A Securities maintaining a Buy rating and raising the price target from $56.2 to $58.2 [4] - GLOBALFOUNDRIES Inc. (NASDAQ: GFS) rose 5% to $37.40 following a collaboration announcement with Corning for developing detachable fiber connector solutions [4]

Core Insights - President Trump's recent post on Truth Social highlighted the potential benefits of cannabidiol in senior healthcare, leading to increased trading activity in cannabis stocks [3][4]. Company Performance - Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) is trading at 6.32, up 1.46, with a trading volume exceeding 5.8 million shares on the Nasdaq [3]. - Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY) is trading at 1.6450, gaining 0.4950, which represents a 42.92% increase, with a trading volume over 145 million shares on the Nasdaq [4]. - Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) is trading at 3.9800, up 0.6800, reflecting a 20.61% rise on the TSX [4].

Group 1 - Norwegian Cruise Line is making headlines as it rings the opening bell at the New York Stock Exchange [1] - Arc Best is also active at NASDAQ, with a positive sentiment among investors despite potential risks from a government shutdown [2][5] - The tech-heavy NASDAQ composite is showing gains, with a rise of approximately 0.5% [6] Group 2 - Electronic Arts shares are up 5% following news of a record-breaking $55 billion deal to take the company private, ending its 36-year run as a public firm [7] - Cannabis stocks are experiencing significant movement, with Tillray up over 28% and Canopy Growth up 13%, driven by President Trump's comments on CBD benefits [8] Group 3 - The potential government shutdown could lead to the furlough of around 900,000 federal employees, which may delay key economic data releases, including the jobs report [11][19] - Goldman Sachs has raised concerns about the market being in a bubble while also indicating that the economic impact of a shutdown would be modest [12][19] - Historically, stocks tend to rebound after a government shutdown, with an average rise of about 3% one month later [20] Group 4 - The U.S. economy is showing mixed signals, with a second-quarter GDP increase of 3.8% driven by consumer spending, but weak labor market readings, including only 22,000 jobs added in August [38][39] - The upcoming jobs report is crucial, with economists expecting an increase of 45,000 jobs for September [39][45] Group 5 - The Federal Reserve is closely monitoring the labor market, with expectations of potential rate cuts in response to economic conditions [18][34] - Analysts suggest that the labor market may see a reacceleration in job growth, particularly in sectors like financial services and construction, as the economy continues to grow [51][52] Group 6 - Gold prices are reaching new highs, driven by government shutdown risks and expectations of further Fed easing, with Goldman Sachs projecting gold could reach $4,000 by mid-2026 [23][24] - Central bank holdings of gold have surpassed U.S. treasuries for the first time since 1996, indicating a significant shift in investment strategies [25]

Group 1: Market Overview - US stock futures are starting the week positively, with expectations for a busy week of economic data and Federal Reserve commentary [1][4] - The Nasdaq is indicating a gain of almost 0.75%, while the S&P and Dow are also showing gains of more than 0.5% [4] - Goldman Sachs has upgraded equities to overweight, citing a resilient US economy and predicting the S&P 500 could climb another 2% to around 6,800 in the coming months [23][39] Group 2: Government Shutdown Implications - Congress is under pressure to reach a deal on a short-term spending bill, with a deadline approaching that could lead to a government shutdown [2][3] - If a shutdown occurs, it could delay key economic reports, including the non-farm payroll report, which is critical for Federal Reserve decision-making [14][15] - The potential for mass layoffs in the federal workforce has been highlighted, with implications for the economy if the shutdown proceeds [16][21] Group 3: Company News - Electronic Arts (EA) is going private in the largest leveraged buyout ever, with a deal valuing the company at $55 billion [3][36] - CSX's CEO has abruptly departed amid pressure from an activist investor and competitive challenges, with a new CEO appointed immediately [37] - Pot stocks are experiencing a boost following President Trump's social media post promoting the medical benefits of hemp-derived CBD, impacting shares of companies like Tilray and Canopy Growth [38] Group 4: Tariffs and Economic Impact - New tariffs are set to take effect this week on various goods, including pharmaceuticals and foreign-made movies, adding uncertainty to the market [5][29] - The imposition of tariffs is causing concern among small businesses, which are particularly affected by the erratic nature of tariff discussions [31][32] - The upcoming earnings season is deemed crucial for the sustainability of the current stock market rally, with analysts noting the potential for volatility due to tariffs and economic conditions [25][52]

Core Viewpoint - President Donald Trump's recent video on Truth Social has reignited interest in cannabis, particularly its potential health benefits and the possibility of changes in federal drug policy [1][2]. Group 1: Health Benefits of Cannabis - The video, produced by The Commonwealth Project, advocates for CBD to be covered under Medicare, labeling it as "the most important senior health initiative of the century" [2]. - It claims that CBD could slow disease progression and serve as an alternative to many prescription drugs for older adults, potentially saving the healthcare system $64 billion annually if cannabis is fully integrated [2]. Group 2: Federal Policy Implications - Trump's video follows earlier comments indicating that his administration is considering reclassifying cannabis at the federal level, which could lead to reduced criminal penalties and eased operational restrictions for cannabis businesses [2]. Group 3: Market Reaction - The announcement led to a significant rally in cannabis stocks, with Canopy Growth Corp. rising 15% and Tilray Brands, Inc. surging 35% [3]. - Other companies such as Cronos Group, Inc., SNDL Inc., and Aurora Cannabis, Inc. also saw increases of over 20% [3]. - The AdvisorShares Pure US Cannabis ETF experienced a nearly 20% increase, reflecting the overall positive market sentiment towards the cannabis sector [4].